ADMA Biologics, Inc.
ADMA
$8.41
$0.536.73%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 10.99% | 19.63% | 27.62% | 43.58% | 62.22% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.99% | 19.63% | 27.62% | 43.58% | 62.22% |
| Cost of Revenue | -9.36% | 5.08% | 14.41% | 26.74% | 28.49% |
| Gross Profit | 29.34% | 33.35% | 41.12% | 62.77% | 112.56% |
| SG&A Expenses | 13.51% | 23.03% | 39.08% | 43.14% | 38.37% |
| Depreciation & Amortization | -20.00% | -62.37% | -78.18% | -84.31% | -70.19% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.41% | 10.87% | 21.28% | 30.81% | 30.17% |
| Operating Income | 36.05% | 37.74% | 41.91% | 79.43% | 223.04% |
| Income Before Tax | 46.58% | 45.30% | 112.35% | 270.19% | 4,715.18% |
| Income Tax Expenses | 162.08% | 149.65% | -1,127.41% | -1,558.01% | -11,193.78% |
| Earnings from Continuing Operations | -20.03% | -25.67% | 207.41% | 500.57% | 5,772.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.03% | -25.67% | 207.41% | 500.57% | 5,772.73% |
| EBIT | 36.05% | 37.74% | 41.91% | 79.43% | 223.04% |
| EBITDA | 34.31% | 35.71% | 39.00% | 71.97% | 188.29% |
| EPS Basic | -20.91% | -26.97% | 202.99% | 491.41% | 5,113.71% |
| Normalized Basic EPS | 40.22% | 43.36% | 52.25% | 109.51% | 433.52% |
| EPS Diluted | -16.44% | -23.24% | 195.87% | 495.16% | 3,867.13% |
| Normalized Diluted EPS | 42.25% | 45.23% | 53.04% | 108.76% | 427.00% |
| Average Basic Shares Outstanding | 1.37% | 2.53% | 3.52% | 4.14% | 4.25% |
| Average Diluted Shares Outstanding | -0.05% | 1.29% | 3.63% | 4.87% | 6.39% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |